<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025532</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068971</org_study_id>
    <secondary_id>UCSF-H11156-18101-02</secondary_id>
    <secondary_id>UCSF-00455</secondary_id>
    <secondary_id>NCI-T97-0054</secondary_id>
    <nct_id>NCT00025532</nct_id>
  </id_info>
  <brief_title>Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer</brief_title>
  <official_title>A Pre-Phase I Biodistribution Study Of hCC^CH2 Labeled With 131 Iodine In Patients With Gastrointestinal Adenocarcinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver
      tumor-killing substances to them without harming normal cells. This may be an effective
      treatment for gastrointestinal cancer.

      PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy
      in treating patients who have gastrointestinal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the biodistribution and biokinetics of iodine I 131-labeled
      monoclonal antibody CC49-delta CH2 in patients with gastrointestinal adenocarcinoma. II.
      Determine the human anti-human monoclonal antibody response in patients treated with this
      drug.

      OUTLINE: Patients receive iodine I 131-labeled monoclonal antibody CC49-delta CH2 (131I MOAB
      CC49-delta CH2) IV over 5-10 minutes on day 0. Patients also receive unlabeled monoclonal
      antibody CC49-delta CH2 IV over 5 minutes followed by 131I MOAB CC49-delta CH2 IV over 5-10
      minutes on day 28. Patients are followed weekly for 4 months and then every 3 months for 1
      year.

      PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study within 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>April 2001</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>iodine I 131 monoclonal antibody CC49-deltaCH2</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the esophagus, stomach,
        pancreas, colon, or rectum More than 30% positively immunoreactive to monoclonal antibody
        CC49 in the metastatic or primary lesion OR TAG-72 antigen serum level greater than 15
        Measurable or evaluable unresectable or metastatic disease by CT scan

        PATIENT CHARACTERISTICS: Age: 19 and over Performance status: ECOG 0-2 Life expectancy: At
        least 3 months Hematopoietic: WBC greater than 3,500/mm3 Platelet count greater than
        150,000/mm3 Hemoglobin greater than 10 g/dL Hepatic: Bilirubin less than 2.0 mg/dL ALT and
        AST less than 3 times upper limit of normal (ULN) (5 times ULN if liver metastases present)
        PTT less than 37.0 seconds INR less than 2.0 Renal: Creatinine less than 2.0 mg/dL Other:
        No known allergy to murine immunoglobulin No iodine allergy No concurrent illness that
        would preclude study Not pregnant or nursing Negative pregnancy test Fertile patients must
        use effective contraception Must be ambulatory and able to comply with study schedule

        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior murine immunoglobulin Chemotherapy:
        Prior or concurrent chemotherapy allowed Endocrine therapy: Not specified Radiotherapy:
        Prior radiotherapy allowed Surgery: See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret A. Tempero, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Cancer Center and Cancer Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>November 20, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2003</study_first_posted>
  <last_update_submitted>September 13, 2012</last_update_submitted>
  <last_update_submitted_qc>September 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2012</last_update_posted>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage III gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>adenocarcinoma of the stomach</keyword>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Iodine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

